Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 9/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13303916 | 0.91 | SLC6A9 (0.47) | SLC6A9ALDH1A1MAPK1LMNARXFP1 | |
| SCHEMBL3237567 | 0.90 | SLC6A9 (0.47) | SLC6A9ALDH1A1 | |
| SCHEMBL3237351 | 0.88 | SLC6A9 (0.51) | SLC6A9ALDH1A1 | |
| SCHEMBL3237145 | 0.84 | AVPR2 (0.43) | SLC6A9ALDH1A1L3MBTL1LMNANPSR1 | |
| SCHEMBL3240768 | 0.84 | SLC6A9 (0.58) | SLC6A9ALDH1A1MAPK1 | |
| SCHEMBL3238379 | 0.84 | ACLY (0.45) | SLC6A9ALDH1A1MAPK1L3MBTL1LMNA | |
| SCHEMBL3237933 | 0.84 | TAS1R3 (0.46) | SLC6A9ALDH1A1L3MBTL1LMNA | |
| SCHEMBL3243915 | 0.83 | SLC6A9 (0.47) | SLC6A9ALDH1A1 | |
| SCHEMBL3243558 | 0.82 | ROCK2 (0.44) | SLC6A9ALDH1A1MAPK1LMNARXFP1 | |
| SCHEMBL3240614 | 0.81 | SLC6A9 (0.56) | SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-7745642-B2 | Glycine transport inhibitors | GLAXO GROUP LIMITED (GB) | 2010-06-29 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287547-A1 | Glycine Transport Inhibitors | GLAXO GROUP LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287547-A1 | Glycine Transport Inhibitors | SLC18A2, SLC6A5, SLC1A2 | SLC6A9 13/4885ALDH1A1 1356/4885MAPK1 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.